Rigel files patent lawsuit against Annora to block generic TAVALISSE

RIGEL PHARMACEUTICALS INC

Filed suit in U.S. District Court for New Jersey against Annora Pharma, Hetero Labs, and Hetero USA for patent infringement.
Lawsuit responds to Annora's ANDA seeking FDA approval for a generic version of TAVALISSE (fostamatinib).
Annora sent Paragraph IV Notice Letter in June 2022 alleging the five asserted patents are invalid or not infringed.
Asserted patents: 7,449,458, 8,263,122, 8,652,492, 8,771,648, and 8,951,504 listed in the FDA Orange Book.
Rigel seeks equitable relief to enjoin Annora from infringing the patents covering TAVALISSE.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.